Global Familial Amyloid Polyneuropathy Therapeutic Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Familial Amyloid Polyneuropathy Therapeutic Market Insights, Forecast to 2034

Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).
Market Analysis and InsightsGlobal Familial Amyloid Polyneuropathy Therapeutic Market
Global Familial Amyloid Polyneuropathy Therapeutic market is expected to reach to US$ 1466 million in 2024, with a positive growth of %, compared with US$ 1387 million in 2022. Backed with the increasing demand from downstream industries, Familial Amyloid Polyneuropathy Therapeutic industry is evaluated to reach US$ 2067.8 million in 2029. The CAGR will be 5.9% during 2024 to 2029.
The global familial amyloid polyneuropathy (FAP) therapeutic market refers to the market for treatments and therapies aimed at managing and treating familial amyloid polyneuropathy, also known as transthyretin amyloidosis (ATTR). FAP is a rare, progressive, and potentially fatal genetic disorder that affects the peripheral nerves and can lead to various symptoms and complications.
Here are some key points related to the global FAP therapeutic market
Market OverviewThe market for FAP therapeutics includes pharmaceutical drugs, gene therapies, and other treatment options aimed at managing the symptoms and halting the progression of the disease.
Disease-Modifying TherapiesThe development of disease-modifying therapies targeting the underlying cause of FAP is a significant focus in this market. These therapies aim to reduce the buildup of abnormal amyloid proteins in the peripheral nerves, which is a hallmark of FAP.
TTR StabilizersTTR (transthyretin) stabilizers are pharmacological agents that aim to stabilize the mutated TTR protein and prevent its misfolding and aggregation. Several TTR stabilizers have been approved or are under investigation for their efficacy in treating FAP.
RNA Interference (RNAi) TherapiesRNAi therapies, such as patisiran and inotersen, work by reducing the production of the TTR protein by interfering with the mRNA responsible for its synthesis. These therapies have shown promise in clinical trials and have been approved for the treatment of FAP in some regions.
Liver TransplantationIn some cases, liver transplantation may be considered as a treatment option for FAP. As the liver produces most of the circulating TTR, replacing the diseased liver with a healthy one can halt the production of mutant TTR and slow down the progression of the disease.
Geographic ConsiderationsThe global FAP therapeutic market is influenced by factors such as regional prevalence, healthcare infrastructure, regulatory environments, and reimbursement policies across different countries and regions.
Ongoing Research and DevelopmentThe FAP therapeutic market is dynamic, with ongoing research and development efforts focusing on novel therapies and treatment modalities. This includes gene therapies, small molecule inhibitors, and other approaches aimed at providing effective and targeted treatments for FAP.
Report Covers
This report presents an overview of global Familial Amyloid Polyneuropathy Therapeutic market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Familial Amyloid Polyneuropathy Therapeutic market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report

By Company

Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc
Prothena Corporation
Eidos Therapeutics
FoldRx Pharmaceuticals
Akcea Therapeutics
GlaxoSmithKline (GSK)
Greenovation Biotech GmbH
Segment by Type
Inotersen
Tafamidis
Patisiran
Others

Segment by Application

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline

Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Familial Amyloid Polyneuropathy Therapeutic introduction, etc. Familial Amyloid Polyneuropathy Therapeutic Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Familial Amyloid Polyneuropathy Therapeutic
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Inotersen
1.2.3 Tafamidis
1.2.4 Patisiran
1.2.5 Others
1.3 Market by Application
1.3.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Perspective (2018-2029)
2.2 Global Familial Amyloid Polyneuropathy Therapeutic Growth Trends by Region
2.2.1 Familial Amyloid Polyneuropathy Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Region (2018-2024)
2.2.3 Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2024-2029)
2.3 Familial Amyloid Polyneuropathy Therapeutic Market Dynamics
2.3.1 Familial Amyloid Polyneuropathy Therapeutic Industry Trends
2.3.2 Familial Amyloid Polyneuropathy Therapeutic Market Drivers
2.3.3 Familial Amyloid Polyneuropathy Therapeutic Market Challenges
2.3.4 Familial Amyloid Polyneuropathy Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Familial Amyloid Polyneuropathy Therapeutic by Players
3.1.1 Global Familial Amyloid Polyneuropathy Therapeutic Revenue by Players (2018-2024)
3.1.2 Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Players (2018-2024)
3.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Familial Amyloid Polyneuropathy Therapeutic, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio
3.4.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2022
3.5 Global Key Players of Familial Amyloid Polyneuropathy Therapeutic Head office and Area Served
3.6 Global Key Players of Familial Amyloid Polyneuropathy Therapeutic, Product and Application
3.7 Global Key Players of Familial Amyloid Polyneuropathy Therapeutic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Type
4.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Type (2018-2024)
4.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Type (2024-2029)
5 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Application
5.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Application (2018-2024)
5.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
6.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type
6.2.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024)
6.2.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029)
6.2.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
6.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
6.3.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024)
6.3.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029)
6.3.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
6.4 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
6.4.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024)
6.4.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
7.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Type
7.2.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024)
7.2.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029)
7.2.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
7.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
7.3.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024)
7.3.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029)
7.3.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
7.4 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
7.4.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024)
7.4.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
8.2 China Familial Amyloid Polyneuropathy Therapeutic Market Size by Type
8.2.1 China Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024)
8.2.2 China Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029)
8.2.3 China Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
8.3 China Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
8.3.1 China Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024)
8.3.2 China Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029)
8.3.3 China Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
9.2 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Type
9.2.1 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024)
9.2.2 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029)
9.2.3 Asia Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
9.3 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
9.3.1 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024)
9.3.2 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029)
9.3.3 Asia Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
9.4 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Region
9.4.1 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2018-2024)
9.4.3 Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type
10.2.1 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
10.3.1 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
10.4.1 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Details
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.1.4 Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.1.5 Pfizer Inc. Recent Developments
11.2 Alnylam Pharmaceuticals Inc.
11.2.1 Alnylam Pharmaceuticals Inc. Company Details
11.2.2 Alnylam Pharmaceuticals Inc. Business Overview
11.2.3 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.2.4 Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.2.5 Alnylam Pharmaceuticals Inc. Recent Developments
11.3 Ionis Pharmaceuticals Inc.
11.3.1 Ionis Pharmaceuticals Inc. Company Details
11.3.2 Ionis Pharmaceuticals Inc. Business Overview
11.3.3 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.3.4 Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.3.5 Ionis Pharmaceuticals Inc. Recent Developments
11.4 Corino Therapeutics Inc.
11.4.1 Corino Therapeutics Inc. Company Details
11.4.2 Corino Therapeutics Inc. Business Overview
11.4.3 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.4.4 Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.4.5 Corino Therapeutics Inc. Recent Developments
11.5 Proclara Biosciences
11.5.1 Proclara Biosciences Company Details
11.5.2 Proclara Biosciences Business Overview
11.5.3 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Introduction
11.5.4 Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.5.5 Proclara Biosciences Recent Developments
11.6 Arcturus Therapeutics Inc
11.6.1 Arcturus Therapeutics Inc Company Details
11.6.2 Arcturus Therapeutics Inc Business Overview
11.6.3 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Introduction
11.6.4 Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.6.5 Arcturus Therapeutics Inc Recent Developments
11.7 Prothena Corporation
11.7.1 Prothena Corporation Company Details
11.7.2 Prothena Corporation Business Overview
11.7.3 Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Introduction
11.7.4 Prothena Corporation Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.7.5 Prothena Corporation Recent Developments
11.8 Eidos Therapeutics
11.8.1 Eidos Therapeutics Company Details
11.8.2 Eidos Therapeutics Business Overview
11.8.3 Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Introduction
11.8.4 Eidos Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.8.5 Eidos Therapeutics Recent Developments
11.9 FoldRx Pharmaceuticals
11.9.1 FoldRx Pharmaceuticals Company Details
11.9.2 FoldRx Pharmaceuticals Business Overview
11.9.3 FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Introduction
11.9.4 FoldRx Pharmaceuticals Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.9.5 FoldRx Pharmaceuticals Recent Developments
11.10 Akcea Therapeutics
11.10.1 Akcea Therapeutics Company Details
11.10.2 Akcea Therapeutics Business Overview
11.10.3 Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Introduction
11.10.4 Akcea Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.10.5 Akcea Therapeutics Recent Developments
11.11 GlaxoSmithKline (GSK)
11.11.1 GlaxoSmithKline (GSK) Company Details
11.11.2 GlaxoSmithKline (GSK) Business Overview
11.11.3 GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Introduction
11.11.4 GlaxoSmithKline (GSK) Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.11.5 GlaxoSmithKline (GSK) Recent Developments
11.12 Greenovation Biotech GmbH
11.12.1 Greenovation Biotech GmbH Company Details
11.12.2 Greenovation Biotech GmbH Business Overview
11.12.3 Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Introduction
11.12.4 Greenovation Biotech GmbH Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
11.12.5 Greenovation Biotech GmbH Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Inotersen
Table 3. Key Players of Tafamidis
Table 4. Key Players of Patisiran
Table 5. Key Players of Others
Table 6. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 7. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 9. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2018-2024)
Table 10. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2024-2029)
Table 12. Familial Amyloid Polyneuropathy Therapeutic Market Trends
Table 13. Familial Amyloid Polyneuropathy Therapeutic Market Drivers
Table 14. Familial Amyloid Polyneuropathy Therapeutic Market Challenges
Table 15. Familial Amyloid Polyneuropathy Therapeutic Market Restraints
Table 16. Global Familial Amyloid Polyneuropathy Therapeutic Revenue by Players (2018-2024) & (US$ Million)
Table 17. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Players (2018-2024)
Table 18. Global Top Familial Amyloid Polyneuropathy Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2022)
Table 19. Global Familial Amyloid Polyneuropathy Therapeutic Industry Ranking 2021 VS 2022 VS 2024
Table 20. Global 5 Largest Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue (CR5 and HHI) & (2018-2024)
Table 21. Global Key Players of Familial Amyloid Polyneuropathy Therapeutic, Headquarters and Area Served
Table 22. Global Key Players of Familial Amyloid Polyneuropathy Therapeutic, Product and Application
Table 23. Global Key Players of Familial Amyloid Polyneuropathy Therapeutic, Product and Application
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 26. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Type (2018-2024)
Table 27. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Type (2024-2029)
Table 29. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 30. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Application (2018-2024)
Table 31. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Application (2024-2029)
Table 33. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 34. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 35. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 36. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 37. North America Familial Amyloid Polyneuropathy Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 39. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 40. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 41. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 42. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 43. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 44. Europe Familial Amyloid Polyneuropathy Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 46. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 47. China Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 48. China Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 49. China Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 50. China Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 51. Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 52. Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 53. Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 54. Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 55. Asia Familial Amyloid Polyneuropathy Therapeutic Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 56. Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 57. Asia Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2024-2029) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Type (2024-2029) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2024-2029) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 63. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 64. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 65. Pfizer Inc. Company Details
Table 66. Pfizer Inc. Business Overview
Table 67. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 68. Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 69. Pfizer Inc. Recent Developments
Table 70. Alnylam Pharmaceuticals Inc. Company Details
Table 71. Alnylam Pharmaceuticals Inc. Business Overview
Table 72. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 73. Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 74. Alnylam Pharmaceuticals Inc. Recent Developments
Table 75. Ionis Pharmaceuticals Inc. Company Details
Table 76. Ionis Pharmaceuticals Inc. Business Overview
Table 77. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 78. Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 79. Ionis Pharmaceuticals Inc. Recent Developments
Table 80. Corino Therapeutics Inc. Company Details
Table 81. Corino Therapeutics Inc. Business Overview
Table 82. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 83. Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 84. Corino Therapeutics Inc. Recent Developments
Table 85. Proclara Biosciences Company Details
Table 86. Proclara Biosciences Business Overview
Table 87. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product
Table 88. Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 89. Proclara Biosciences Recent Developments
Table 90. Arcturus Therapeutics Inc Company Details
Table 91. Arcturus Therapeutics Inc Business Overview
Table 92. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product
Table 93. Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 94. Arcturus Therapeutics Inc Recent Developments
Table 95. Prothena Corporation Company Details
Table 96. Prothena Corporation Business Overview
Table 97. Prothena Corporation Familial Amyloid Polyneuropathy Therapeutic Product
Table 98. Prothena Corporation Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 99. Prothena Corporation Recent Developments
Table 100. Eidos Therapeutics Company Details
Table 101. Eidos Therapeutics Business Overview
Table 102. Eidos Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product
Table 103. Eidos Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 104. Eidos Therapeutics Recent Developments
Table 105. FoldRx Pharmaceuticals Company Details
Table 106. FoldRx Pharmaceuticals Business Overview
Table 107. FoldRx Pharmaceuticals Familial Amyloid Polyneuropathy Therapeutic Product
Table 108. FoldRx Pharmaceuticals Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 109. FoldRx Pharmaceuticals Recent Developments
Table 110. Akcea Therapeutics Company Details
Table 111. Akcea Therapeutics Business Overview
Table 112. Akcea Therapeutics Familial Amyloid Polyneuropathy Therapeutic Product
Table 113. Akcea Therapeutics Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 114. Akcea Therapeutics Recent Developments
Table 115. GlaxoSmithKline (GSK) Company Details
Table 116. GlaxoSmithKline (GSK) Business Overview
Table 117. GlaxoSmithKline (GSK) Familial Amyloid Polyneuropathy Therapeutic Product
Table 118. GlaxoSmithKline (GSK) Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 119. GlaxoSmithKline (GSK) Recent Developments
Table 120. Greenovation Biotech GmbH Company Details
Table 121. Greenovation Biotech GmbH Business Overview
Table 122. Greenovation Biotech GmbH Familial Amyloid Polyneuropathy Therapeutic Product
Table 123. Greenovation Biotech GmbH Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024) & (US$ Million)
Table 124. Greenovation Biotech GmbH Recent Developments
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Type: 2022 VS 2029
Figure 3. Inotersen Features
Figure 4. Tafamidis Features
Figure 5. Patisiran Features
Figure 6. Others Features
Figure 7. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Familial Amyloid Polyneuropathy Therapeutic Report Years Considered
Figure 14. Global Familial Amyloid Polyneuropathy Therapeutic Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Familial Amyloid Polyneuropathy Therapeutic Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region: 2022 VS 2029
Figure 17. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Players in 2022
Figure 18. Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2022
Figure 20. North America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
Figure 22. North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
Figure 23. North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)
Figure 24. United States Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
Figure 28. Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
Figure 29. Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)
Figure 30. Germany Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Familial Amyloid Polyneuropathy Therapeutic Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
Figure 38. China Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
Figure 39. Asia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
Figure 41. Asia Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
Figure 42. Asia Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2018-2029)
Figure 43. Japan Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Country (2018-2029)
Figure 53. Brazil Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Pfizer Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 60. Alnylam Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 61. Ionis Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 62. Corino Therapeutics Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 63. Proclara Biosciences Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 64. Arcturus Therapeutics Inc Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 65. Prothena Corporation Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 66. Eidos Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 67. FoldRx Pharmaceuticals Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 68. Akcea Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 69. GlaxoSmithKline (GSK) Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 70. Greenovation Biotech GmbH Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2018-2024)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

Global Familial Amyloid Polyneuropathy Therapeutic Market Insights, Forecast to 2034

Global Familial Amyloid Polyneuropathy Therapeutic Market Insights, Forecast to 2034

By Company

Segment by Application

Chapter Outline

Table of Content

List of Figure

Select User License

$4200 Single Licence

$6000 Enterprise Licence

$9100 Corporate Licence

Note : All prices in USD

FAQ'S

User License?

Delivery Time?

How do I place an order?

What is the Payment Options?

Is there a discount for multiple purchases?

Mode of Report Delivery?

Top Industries